Medicine, Gastroenterology Division

Grants

Grants per year 2001 2014 2015 2016 2017 2018 2019 2020 2028

• 61 Active
• 168 Finished

Grants per year

Search results

• Active

  Prot #Vedolizumab-4033: ENTYVIO(R) Long-Term Real-World Outcomes in Bio-naïve Ulcerative Colitis and Crohn's Disease Patients in Canada and the US: An EVOLVE Observational Follow-up Study

  Bellaguarda, E. A. L.

  PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.

  11/1/22 → 11/1/25

  Project: Research project

• Prot #MORF-057-201: A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults with Moderate to Severe Ulcerative Colitis (EMERALD-1)

  Dulai, P. S.

  PSI Pharma Support America Inc., Morphic Therapeutic, Inc.

  10/25/22 → 10/25/25

  Project: Research project

• Prot #TA799-007: A Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Apraglutide in Adult Subjects with Short Bowel Syndrome and Intestinal Failure (SBS-IF)

  Stein, A. C.

  PSI Pharma Support America Inc., VectivBio AG

  10/24/22 → 10/24/25

  Project: Research project

• Prot #D3258C00001: A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study

  Hirano, I.

  AstraZeneca Pharmaceuticals LP

  9/16/22 → 9/16/25

  Project: Research project

• Prot #MDR20111: Cook Nasal Jejunal Feeding Tubes Study

  Komanduri, S.

  Cook Research Incorporated

  9/14/22 → 9/14/25

  Project: Research project

• Development and validation of machine learning optimized predictive models for response to different biologic agents in patients with Crohn's disease and ulcerative colitis

  Dulai, P. S.

  American Gastroenterological Association Institute

  9/1/22 → 4/30/23

  Project: Research project

  • Biological Product 100%
  • Inflammatory Bowel Disease 36%
  • Clinical Trial 27%
  • Tumor Necrosis Factor 27%
  • Ulcerative Colitis 27%

• Prot #CC-93538-EE-001: A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Eosinophilic Esophagitis

  Hirano, I.

  PPD Investigator Services, LLC, Celgene International II Sàrl

  8/17/22 → 8/17/25

  Project: Research project

• Optimizing Implementation of Treat-to-Target in Inflammatory Bowel Disease

  Dulai, P. S.

  Pfizer Inc.

  6/16/22 → 6/15/23

  Project: Research project

  • Inflammatory Bowel Disease 100%
  • implementation 66%
  • Wellbeing 38%
  • Biological Marker 38%
  • Serositis 38%

• Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF (STRONG-CF)

  Stein, A. C.

  Cystic Fibrosis Foundation

  6/1/22 → 5/31/28

  Project: Research project

  • Body Composition 100%
  • Measurement 85%
  • Body Mass Index 85%
  • Body Weight 85%
  • Dual-Energy X-Ray Absorptiometry 85%

• Prot #CM4620-203: A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study of Auxora in Patients with Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (CARPO)

  Keswani, R. N.

  Emas Pharma Limited, CalciMedica, Inc.

  4/28/22 → 4/28/25

  Project: Research project

• Targeting Hypervigilance and Autonomic Arousal: the Psycho-physiologic Model of GERD

  Pandolfino, J. E., Taft, T. N., Pandit, A. U., Schauer, J. M. & Tomasino, K. N.

  National Institute of Diabetes and Digestive and Kidney Diseases

  4/1/22 → 3/31/27

  Project: Research project

  • Hypervigilance 100%
  • Psychological Distress 50%
  • Cognitive-Behavioral Intervention 41%
  • Behavioral Intervention 41%
  • patients 41%

• Prot#MDR-20112: Cook Sphincterotomes and Active Cords

  Komanduri, S.

  Cook Research Incorporated

  3/17/22 → 3/17/25

  Project: Research project

• Developing a Chronic Opioid Use Assessment and Screening Tool for Adolescents with Inflammatory Bowel Disease

  Balbale, S. N.

  Crohn's and Colitis Foundation of America

  1/1/22 → 12/31/24

  Project: Research project

  • Opiate 100%
  • Inflammatory Bowel Disease 80%
  • Clinician 70%
  • Patient 50%
  • Assessment 40%

• Prot#TAK-018-2001: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence

  Bellaguarda, E. A. L.

  Pharmaceutical Research Associates, Inc., Millennium Pharmaceuticals, Inc

  12/17/21 → 12/17/24

  Project: Research project

• Prot#EG-CL-102: A Multicenter Case-Control Study of the Efficacy of EsoGuard on Samples Collected Using EsoCheck, Versus Esophagogastroduodenoscopy, for the Diagnosis of Barrett's Esophagus with and without Dysplasia, and for Esophageal Adenocarcinoma

  Komanduri, S.

  Lucid Diagnostics, Inc.

  12/10/21 → 12/10/24

  Project: Research project

• Prot#MA39975: A Multicenter, Retrospective, Observational Study to Evaluate the Association between Histological Remission and Long-Term Outcomes in Patients with Ulcerative Colitis

  Hanauer, S. B.

  PPD Investigator Services, LLC, Genentech, Inc.

  12/7/21 → 12/7/24

  Project: Research project

• Prot#APD334-206: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis

  Hirano, I.

  Quintiles, Inc., Arena Pharmaceuticals, Inc.

  9/14/21 → 9/14/24

  Project: Research project

• SpHincterotomy for Acute Recurrent Pancreatitis Trial (SHARP)

  Keswani, R. N.

  Oregon Health and Science University, National Institute of Diabetes and Digestive and Kidney Diseases

  9/3/21 → 8/31/23

  Project: Research project

  • Acute Pancreatitis 100%
  • Chronic Pancreatitis 42%
  • risks 42%
  • Therapeutic Procedure 28%
  • pancreas 28%

• Data Coordinating Center for the Type 1 Diabetes in Acute Pancreatitis Consortium

  Keswani, R. N.

  Pennsylvania State University, National Institute of Diabetes and Digestive and Kidney Diseases

  8/1/21 → 7/31/25

  Project: Research project

  • Diabetes 100%
  • Acute Pancreatitis 75%
  • Diabetes Mellitus 75%
  • Insulin Dependent Diabetes Mellitus 29%
  • Health Disparity 29%

• Data Coordinating Center for the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)

  Keswani, R. N.

  Pennsylvania State University, National Institute of Diabetes and Digestive and Kidney Diseases

  8/1/21 → 7/31/25

  Project: Research project

  • Diabetes 100%
  • Acute Pancreatitis 75%
  • Diabetes Mellitus 75%
  • Insulin Dependent Diabetes Mellitus 29%
  • Health Disparity 29%

• Prot# Cx601-0303: A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex

  Bellaguarda, E. A. L. & Hanauer, S. B.

  Parexel, TiGenix, S.A.U.

  7/30/21 → 7/30/24

  Project: Research project

• Prot#AK002-016X: A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (f

  Gonsalves, N. P.

  Allakos, Inc.

  7/12/21 → 7/12/24

  Project: Research project

• Prot#TRACT-CD-201: A Phase IB Study to Investigate the Safety, Tolerability and Efficacy of T Regulatory Cells for the Treatment of Moderate to Severe Active Crohn's Disease Refractory to Conventional and/or Biological Therapy

  Hanauer, S. B.

  TRACT Therapeutics, Inc.

  6/25/21 → 6/25/24

  Project: Research project

• Prot #RCT01437: Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: The OPTIMIZE Trial

  Hanauer, S. B.

  Beth Israel Deaconess Medical Center, Leona M. and Harry B. Helmsley Charitable Trust

  3/1/21 → 2/29/24

  Project: Research project

• Prot#AK002-014: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis

  Hirano, I.

  Allakos, Inc.

  1/8/21 → 1/8/24

  Project: Research project